Authors
Latest:
Pandemic Inspires New Outreach ProgramAs oncologists, we are here to help patients and their families as much as we can. That is why we went into cancer medicine. It is what we do every day. Until the coronavirus disease 2019 pandemic knocked on our doors.
Latest:
Dr Richter on the Current State of Bispecific Antibodies in Multiple MyelomaJoshua Richter, MD, discusses how bispecific antibodies fit into the current treatment armamentarium for patients with multiple myeloma, highlighting his presentation from the 41st Annual CFS®.
Latest:
Investigational Agents for Relapsed/Refractory MyelomaKeith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Latest:
Dr. Fausel on the Evolution of Genomic Testing in Cancer CareChristopher A. Fausel, PharmD, MHA, BCOP, discusses how genetic sequencing has played a growing role in cancer care.
Latest:
Optimizing Treatment Selection for Patients with FLT3-ITD AMLDiscussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.
Latest:
Precision Epigenetic Targeting for Germinal Cancer LymphomasJennifer Effie Amengual, MD, of Columbia University Hebert Irving Comprehensive Cancer Center, discusses precision epigenetic targeting for germinal cancer lymphomas.
Latest:
Dr. Zeiser on Results of the REACH3 Trial in Chronic GVHDRobert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.
Latest:
How Biomarker Testing Could Continue to Evolve in NSCLCJessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Latest:
Dr. Tilly on Pola-R-CHP in an Asia Subpopulation of Patients With DLBCLHervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.
Latest:
Dr Birrer on Molecular Stratification in Endometrial CancerMichael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.
Latest:
FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ AdenocarcinomaDr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma.
Latest:
Dr. Hales on the Role of Multidisciplinary Care in Locally Advanced Lung CancerRussell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer.
Latest:
Dr. Matsen on the Effects of Decreased Breast Cancer Screening in the COVID-19 EraCindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.
Latest:
Dr Rahimi on Escalating Preoperative, Single-Fraction Ablative Radiation in HR-Positive Breast CancerAsal Rahimi, MD, MS, discusses initial efficacy results from the expanded cohort of a phase 1 dose-escalation study (NCT04040569) evaluating pre-operative, single fraction stereotactic ablative radiation in early-stage, hormone receptor–positive breast cancer.
Latest:
Narsoplimab: The Phase 2 TrialSamer Khaled, MD reviews the design, results, and practical implications of the pivotal phase 2 trial of narsoplimab, a MASP-2 targeted monoclonal antibody under investigation for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation.
Latest:
Advice for New Nurse Practitioners Working With Patients With Endometrial CancerClosing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.
Latest:
Evolving Psychosocial Care Models Step Forward as the Next Targeted Cancer TherapyDuring this search for a breast cancer support system, my mother also investigated complementary therapies that peers had used to help cope with their fears, adverse effects, and feelings of helplessness.
Latest:
Dr Pabon on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ AdenocarcinomaCindy Medina Pabon, MD, discusses the clinical relevance of the FDA approval of zolbetuximab for CLDN18.2-positive gastric or GEJ adenocarcinoma.
Latest:
Dr Kadia on Targeting the IRAK4 Pathway in AMLTapan M. Kadia, MD, discusses targeting the IRAK4 pathway in patients with acute myeloid leukemia and highlights the importance of utilizing targeted therapies in the treatment of patients with hematologic malignancies.
Latest:
Women in Oncology: Lessons to Tell Up-and-Coming Female OncologistsLaura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.
Latest:
Dr. Lee on the Current State of Molecular Testing in Early-Stage NSCLCJay Moon Lee, MD, discusses the current state of molecular testing in early-stage non–small cell lung cancer.
Latest:
Breast Nerve Preservation and Grafting: How Surgeons Can Help Mitigate Sensation LossMore surgeons are having in-depth conversations with their patients with breast cancer and prophylactic patients about the fact that nerves will have to be cut during their mastectomy, how that will impact sensation and quality of life, and how surgeon collaboration and breast neurotization can help restore sensation.
Latest:
Women in Oncology: Prioritization and Passionate LegaciesSelina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.
Latest:
Dr. Colombo on the Next Steps With Pembrolizumab in Cervical CancerNicoletta Colombo, MD, PhD, discusses the next steps with pembrolizumab in cervical cancer.
Latest:
Dr Oluwole on the Use of CAR T-Cell Therapy in Autoimmune DisordersOlalekan O. Oluwole, MBBS, MD, discusses the feasibility of using CAR T-cell therapy in patients with nonhematologic autoimmune disorders.
Latest:
Women in Oncology: Leaving Passionate LegaciesCourtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.
Latest:
Dr. Kim on Optimizing Individualized Treatment in Cancer CareMichelle Miran Kim, MD, discusses optimizing individualized treatment in cancer care.
Latest:
Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric CancerShared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.
Latest:
Dr. Lower on the Importance of Tucatinib Plus Capecitabine/Trastuzumab in HER2+ Breast CancerElyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.
